Scott Gottlieb Buys 500 Shares of Illumina (NASDAQ:ILMN) Stock

Illumina, Inc. (NASDAQ:ILMN) Director Scott Gottlieb acquired 500 shares of the business’s stock in a transaction that occurred on Monday, November 3rd. The shares were purchased at an average price of $122.13 per share, with a total value of $61,065.00. Following the completion of the transaction, the director owned 12,523 shares of the company’s stock, valued at $1,529,433.99. The trade was a 4.16% increase in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

Illumina Stock Performance

NASDAQ:ILMN opened at $121.11 on Friday. The company’s 50-day moving average is $100.07 and its two-hundred day moving average is $93.95. Illumina, Inc. has a 1-year low of $68.70 and a 1-year high of $155.99. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.81 and a quick ratio of 1.41. The firm has a market capitalization of $18.51 billion, a price-to-earnings ratio of 15.33, a PEG ratio of 2.34 and a beta of 1.42.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings results on Thursday, October 30th. The life sciences company reported $1.34 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.16 by $0.18. The business had revenue of $1.08 billion during the quarter, compared to the consensus estimate of $1.07 billion. Illumina had a net margin of 29.36% and a return on equity of 28.93%. The business’s revenue was up .4% compared to the same quarter last year. During the same quarter last year, the firm earned $1.14 EPS. Illumina has set its FY 2025 guidance at 4.650-4.750 EPS. Analysts forecast that Illumina, Inc. will post 4.51 EPS for the current year.

Hedge Funds Weigh In On Illumina

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Rise Advisors LLC increased its position in shares of Illumina by 173.6% during the first quarter. Rise Advisors LLC now owns 353 shares of the life sciences company’s stock worth $28,000 after acquiring an additional 224 shares during the period. Parkside Financial Bank & Trust boosted its holdings in Illumina by 65.7% in the second quarter. Parkside Financial Bank & Trust now owns 290 shares of the life sciences company’s stock valued at $28,000 after purchasing an additional 115 shares during the period. Quent Capital LLC acquired a new position in Illumina during the 3rd quarter worth $29,000. Cullen Frost Bankers Inc. purchased a new stake in Illumina during the 2nd quarter worth about $41,000. Finally, NewSquare Capital LLC boosted its stake in shares of Illumina by 604.9% in the 2nd quarter. NewSquare Capital LLC now owns 430 shares of the life sciences company’s stock valued at $41,000 after buying an additional 369 shares during the period. Hedge funds and other institutional investors own 89.42% of the company’s stock.

Analysts Set New Price Targets

ILMN has been the topic of several recent analyst reports. Morgan Stanley upped their price target on Illumina from $100.00 to $105.00 and gave the company an “equal weight” rating in a research note on Monday, August 4th. Weiss Ratings restated a “sell (d+)” rating on shares of Illumina in a report on Wednesday, October 8th. Daiwa America cut shares of Illumina from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, August 12th. Barclays lifted their price target on shares of Illumina from $95.00 to $100.00 and gave the company an “underweight” rating in a research report on Friday, October 31st. Finally, JPMorgan Chase & Co. boosted their price target on shares of Illumina from $100.00 to $105.00 and gave the company a “neutral” rating in a research note on Friday, October 31st. Five analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and three have issued a Sell rating to the stock. According to MarketBeat, Illumina has a consensus rating of “Hold” and a consensus target price of $115.00.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.